EUVIMEDEUVIMED entdecken
Crossref

The role of IgG1 and IgG4 as dominant IgE-blocking antibodies shifts during allergen immunotherapy

Maria R Strobl, Hilal Demir, Gabriela Sánchez Acosta, Anja Drescher, Claudia Kitzmüller, Christian Möbs, Wolfgang Pfützner, Barbara Bohle

Journal of Allergy and Clinical Immunology · 2023

DOI: 10.1016/j.jaci.2023.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023. Verfasst von Maria R Strobl und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Aus…. Hauptthemen laut MEDLINE: Allergens, Pollen. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Austrian Science Fund FWF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The induction of allergen-specific IgE-blocking antibodies is a hallmark of allergen immunotherapy (AIT). The inhibitory bioactivity has largely been attributed to IgG4; however, our recent studies indicated the dominance of IgG1 early in AIT. OBJECTIVES: Here, the IgE-blocking activity and avidity of allergen-specific IgG1 and IgG4 antibodies were monitored throughout 3 years of treatment. METHODS: Serum samples from 24 patients were collected before and regularly during AIT with birch pollen. Bet v 1-specific IgG1 and IgG4 levels were determined by ELISA and ImmunoCAP, respectively. Unmodified and IgG1- or IgG4-depleted samples were compared for their inhibition of Bet v 1-induced basophil activation. The stability of Bet v 1-antibody complexes was compared by ELISA and by surface plasmon resonance. RESULTS: Bet v 1-specific IgG1 and IgG4 levels peaked at 12 and 24 months of AIT, respectively. Serological IgE-blocking peaked at 6 months and remained high thereafter. In the first year of therapy, depletion of IgG1 clearly diminished the inhibition of basophil activation while the absence of IgG4 hardly reduced IgE-blocking. Then, IgG4 became the main inhibitory isotype in most individuals. Both isotypes displayed high avidity to Bet v 1 ab initio of AIT, which did not increase during treatment. Bet v 1-IgG1 complexes were enduringly more stable than Bet v 1-IgG4 complexes were. CONCLUSIONS: In spite of the constant avidity of AIT-induced allergen-specific IgG1 and IgG4 antibodies, their dominance in IgE-blocking shifted in the course of treatment. The blocking activity of allergen-specific IgG1 should not be underestimated, particularly early in AIT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AllergensPollenHumansAntibodies, BlockingAntigens, PlantImmunoglobulin EDesensitization, ImmunologicImmunoglobulin G

Stichwörter der Autor:innen

Allergen immunotherapyBet v 1IgE-blockingIgG(1)IgG(4)antibodiesaviditybirch pollen

Substanzen

AllergensAntibodies, BlockingAntigens, PlantImmunoglobulin EImmunoglobulin G

Autor:innen und Institutionen

  • Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
  • Cytiva Europe GmbH, Freiburg, Department of Dermatology and Allergology, Philipps-Universität Marburg, Freiburg and Marburg, Germany.
  • Clinical and Experimental Allergology, Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany.
  • Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria. Electronic address: barbara.bohle@meduniwien.ac.at.

Förderung

  • Austrian Science Fund FWF

Zitieren

APA

Strobl, M. R., Demir, H., Sánchez Acosta, G., Drescher, A., Kitzmüller, C., Möbs, C., Pfützner, W., & Bohle, B. (2023). The role of IgG1 and IgG4 as dominant IgE-blocking antibodies shifts during allergen immunotherapy. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.01.005

Vancouver

Strobl MR, Demir H, Sánchez Acosta G, Drescher A, Kitzmüller C, Möbs C, et al. The role of IgG1 and IgG4 as dominant IgE-blocking antibodies shifts during allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2023. doi:10.1016/j.jaci.2023.01.005

BibTeX
@article{Strobl2023,
  author = {Strobl, Maria R and Demir, Hilal and Sánchez Acosta, Gabriela and Drescher, Anja and Kitzmüller, Claudia and Möbs, Christian and Pfützner, Wolfgang and Bohle, Barbara},
  title = {The role of IgG1 and IgG4 as dominant IgE-blocking antibodies shifts during allergen immunotherapy},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  doi = {10.1016/j.jaci.2023.01.005}
}
Kostenlos starten →